Loading...
•
Dec 31, 2025
Exact Sciences Q4 2025 Earnings Report
Exact Sciences reported record fourth quarter 2025 revenue growth, with strong Screening and Precision Oncology performance, while continuing to post a net loss.
Key Takeaways
For Q4 2025, Exact Sciences generated revenue of 878381000, up 23% year-over-year, driven by Screening revenue of 695138000 and Precision Oncology revenue of 183243000. The company reported a net loss of 85955000, or 0.45 per share, and adjusted EBITDA of 63441000 with a 7% margin.
Total revenue increased 23% year-over-year to 878381000.
Screening revenue grew 26% to 695138000, while Precision Oncology increased 14% to 183243000.
Gross margin was 70%, and adjusted gross margin was 73%.
Adjusted EBITDA was 63441000 with a 7% margin, while net loss totaled 85955000.
Revenue by Segment
Forward Guidance
Exact Sciences highlighted continued growth momentum across its core products and pipeline expansion, while the pending merger with Abbott remains subject to regulatory approval and stockholder vote.
Positive Outlook
- Strong double-digit revenue growth in both Screening and Precision Oncology.
- Improved operating cash flow of 151689000 and free cash flow of 120446000 in Q4.
- Robust liquidity with 965000000 in cash, cash equivalents, and marketable securities.
- Expansion of cancer screening portfolio through Freenome license agreement.
- Positive adjusted EBITDA generation during the quarter.
Challenges Ahead
- Net loss widened year-over-year to 85955000.
- Adjusted EBITDA margin declined to 7% from 12% in the prior year quarter.
- Higher R&D expense, including 75000000 related to Freenome collaboration.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...